DATA GRAPHICS | Data Byte
Early data from Novo’s CagriSema competitive with Lilly’s Mounjaro
CagriSema yields more weight loss and HbA1c reduction in Phase II than was seen in early trials of Mounjaro
August 22, 2022 11:45 PM UTC
Phase II results from Novo Nordisk’s semaglutide-cagrilintide combo show potential to compete with Eli Lilly’s recently launched Mounjaro. Novo is advancing CagriSema into Phase III trials for Type II diabetes and obesity.
Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) said CagriSema, a fixed-dose combination of 2.4 mg semaglutide and 2.4 mg cagrilintide, performed better than either agent alone in Type II diabetes patients who were overweight. At week 32, the amylin analogue and GLP-1 analogue reduced HbA1c 2.18% versus 1.79% with semaglutide monotherapy and 0.93% with cagrilintide monotherapy. ...